Flamel picks up first payment on human insulin

- Last updated on GMT

Related tags: Medicine, Bristol-myers squibb, Flamel

French drug delivery firm Flamel Technologies has received a $5
million milestone payment from Bristol-Myers Squibb, which acquired
rights to Flamel's formulation of long-acting human insulin in
August last year.

The licensing deal, valued at up to $165 million at that time, is for a once-daily injectable formulation of insulin, called Basulin, just entering Phase III testing.

Flamel and BMS hope that using human insulin may reduce the risk of side effects caused by immunological responses and extend insulin delivery to include full 24-hour cover.

Flamel is currently developed two polymer-based delivery technologies for medical applications - the Medusa technology, designed to deliver therapeutic proteins and Micropump, a controlled release and taste-masking technology for the oral administration of small molecule drugs.

The company had signed GlaxoSmithkline to apply its Micropump technology to a sachet formulation of Augmentin (amoxicillin/clavulanate), a blockbuster antibiotic but this agreement was terminated in January.

Related topics: Ingredients, Delivery technologies

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Follow us


View more